

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
16 June 2022 (16.06.2022)



(10) International Publication Number
WO 2022/122652 A1

(51) International Patent Classification:
C07K 16/24 (2006.01)

(21) International Application Number:
PCT/EP2021/084400

(22) International Filing Date:
06 December 2021 (06.12.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
20212127.3 07 December 2020 (07.12.2020) EP

(71) Applicant: UCB BIOPHARMA SRL [BE/BE]; 60, Allée de la Recherche, 1070 Brussels (BE).

(72) Inventors: **RASTRICK, Joseph Michael David**; c/o IPD, UCB, 208 Bath Road, Slough Berkshire SL 1 3WE (GB). **SILVA, John Paul**; c/o IPD, UCB, 208 Bath Road, Slough Berkshire SL 1 3WE (GB). **TYSON, Kerry Louise**; c/o IPD, UCB, 208 Bath Road, Slough Berkshire SL 1 3WE (GB). **ELLIOTT, Peter Charles**; c/o IPD, UCB, 208 Bath Road, Slough Berkshire SL 1 3WE (GB). **LEYSEN, Seppe Frans Roman**; c/o IPD, UCB, 208 Bath Road, Slough Berkshire SL 1 3WE (GB). **AHDASH, Zainab**; c/o IPD, UCB, 208 Bath Road, Slough Berkshire SL 1 3WE (GB).

(74) Agent: UCB INTELLECTUAL PROPERTY; c/o UCB Biopharma SRL, 60, Allée de la Recherche, 1070 Brussels (BE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: ANTIBODIES AGAINST INTERLEUKIN-22

(57) Abstract: The present invention relates to antibodies binding to IL22 and inhibiting its interaction with one or more of its natural ligands. Specific examples of such antibodies are provided. The therapeutic uses of the antibodies and methods of generating such are also provided.

WO 2022/122652 A1